

		WB021401 M3110772	AGE/SEX :45 Years Male DRAWN :11/02/2023 08:47:29
	1000	43110772	DRAWN :11/02/2023 08·47·29
		10110772	
	CLIENT PATIENT ID:		RECEIVED : 11/02/2023 08:48:40
	ABHA NO :		REPORTED :13/02/2023 11:36:56
	Results	Biological	Reference Interval Units
H CHECK UP AB	OVE 40 MALE		
	NO ABNORMALITY DE	TECTED	
	NEGATIVE		
	WITHIN NORMAL LIM	ITS	
	NOT SIGNIFICANT		
	OPERATED RIGHT CA	LLAR BONE FRACT	URE - 4 YRS AGO.
/	ALCOHOL - OCC		
	FATHER / MOTHER : I	HYPERTENSION / [DIABETES.
	NOT SIGNIFICANT		
C C C C C C C C C C C C C C C C C C C			
	1.75		mts
	96		Kgs
	31	BMI & We	ight Status as follo \vg /sqmts
			5: Underweight
			.9: Normai .9: Overweight
			Above: Obese
	NORMAL		
	NORMAL		
ITIONAL	HEALTHY		
К	AVERAGE		
	NORMAL		
GLANDS	NOT ENLARGED OR T	ENDER	
	NOT ENLARGED		
Starkl			Page 1 Of 23
	ITIONAL C GLANDS	TH CHECK UP ABOVE 40 MALE NO ABNORMALITY DE NEGATIVE NEGATIVE WITHIN NORMAL LIM NOT SIGNIFICANT OPERATED RIGHT CA ALCOHOL - OCC FATHER / MOTHER : H NOT SIGNIFICANT I.75 96 31 I.75 96 31 NORMAL	TH CHECK UP ABOVE 40 MALE NO ABNORMALITY DETECTED NEGATIVE WITHIN NORMAL LIMITS NOT SIGNIFICANT OPERATED RIGHT CALLAR BONE FRACT ALCOHOL - OCC FATHER / MOTHER : HYPERTENSION / D NOT SIGNIFICANT I I I I I I I I I I I I I I I I I I I



Patient Ref. No. 2000011598668





PATIENT NAME : RAJSHEKAR PABBA	REF. DOCTOR	REF. DOCTOR : SELF		
	ACCESSION NO : 0002WB021401	AGE/SEX :45 Years Male		
	PATIENT ID : RAJSM3110772	DRAWN :11/02/2023 08:47:29		
	CLIENT PATIENT ID:	RECEIVED : 11/02/2023 08:48:40		
	ABHA NO :	REPORTED :13/02/2023 11:36:56		
Test Report Status <u>Final</u>	Results Biologic	al Reference Interval Units		
CAROTID PULSATION	NORMAL			
TEMPERATURE	NORMAL			
PULSE	72/MIN.REGULAR, ALL PERIPHERAL F BRUIT	PULSES WELL FELT, NO CAROTID		
RESPIRATORY RATE	NORMAL			
CARDIOVASCULAR SYSTEM				
BP	130/80 MM HG (SUPINE)	mm/Hg		
PERICARDIUM	NORMAL			
APEX BEAT	NORMAL			
HEART SOUNDS	NORMAL			
MURMURS	ABSENT			
RESPIRATORY SYSTEM				
SIZE AND SHAPE OF CHEST	NORMAL			
MOVEMENTS OF CHEST	SYMMETRICAL			
BREATH SOUNDS INTENSITY	NORMAL			
BREATH SOUNDS QUALITY	VESICULAR (NORMAL)			
ADDED SOUNDS	ABSENT			
PER ABDOMEN				
APPEARANCE	NORMAL			
VENOUS PROMINENCE	ABSENT			
LIVER	NOT PALPABLE			
SPLEEN	NOT PALPABLE			
HERNIA	ABSENT			
CENTRAL NERVOUS SYSTEM				
HIGHER FUNCTIONS	NORMAL			
CRANIAL NERVES	NORMAL			
CEREBELLAR FUNCTIONS	NORMAL			
SENSORY SYSTEM	NORMAL			
MOTOR SYSTEM	NORMAL			
REFLEXES	NORMAL			
MUSCULOSKELETAL SYSTEM				
	NORMAL			

Sexamarkaz

Dr. Swati Karmarkar, MD,DNB,DMRD Consultant Radiologist

Sterkl

Dr. J N Shukla ,MBBS, AFIH Consultant Physician





Page 2 Of 23

View Details



PERFORMED AT : SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



PATIENT NAME: RAJSHEKAR PABBA	REF. DOCTO	R: SELF	
	ACCESSION NO : 0002WB021401	AGE/SEX :45 Years Male	
	PATIENT ID : RAJSM3110772	DRAWN :11/02/2023 08:47:29	
	CLIENT PATIENT ID:	RECEIVED :11/02/2023 08:48:40	
	ABHA NO :	REPORTED :13/02/2023 11:36:56	
Test Report Status <u>Final</u>	Results Biolog	ical Reference Interval Units	
JOINTS	NORMAL		
BASIC EYE EXAMINATION			
CONJUNCTIVA	NORMAL		
EYELIDS	NORMAL		
EYE MOVEMENTS	NORMAL		
CORNEA	NORMAL		
DISTANT VISION RIGHT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT (6/6)		
DISTANT VISION LEFT EYE WITHOUT GLASSES	REDUCE VISUAL ACUITY (6/9)		
NEAR VISION RIGHT EYE WITHOUT GLASSES	REDUCE VISUAL ACUITY (N8)		
NEAR VISION LEFT EYE WITHOUT GLASSES	REDUCE VISUAL ACUITY (N8)		
COLOUR VISION	NORMAL (17/17)		
BASIC ENT EXAMINATION			
EXTERNAL EAR CANAL	NORMAL		
TYMPANIC MEMBRANE	NORMAL		
NOSE	NO ABNORMALITY DETECTED		
SINUSES	NORMAL		
THROAT	NO ABNORMALITY DETECTED		
TONSILS	NOT ENLARGED		
BASIC DENTAL EXAMINATION			
TEETH	NORMAL		
GUMS	HEALTHY		
SUMMARY			
RELEVANT HISTORY	NOT SIGNIFICANT		
RELEVANT GP EXAMINATION FINDINGS	NOT SIGNIFICANT		
RELEVANT LAB INVESTIGATIONS	RAISED ESR (18) RAISED HBA1C (6.7) RAISED EAG (145.6) RAISED FBS (117) RAISED PPBS (154) LOW HDL CHOLESTEROL (30) RAISED LDL (110) RAISED NON HDL (132) RAISED URIC ACID (8.5) STOOL-OCCULT BLOOD DETECTED		

Sexamarkaz

Herkl

Dr. Swati Karmarkar, MD, DNB, DMRD **Consultant Radiologist** Dr. J N Shukla ,MBBS, AFIH **Consultant Physician**



See. View Report

i 🗖

Page 3 Of 23

PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

<u>View Details</u>



PERFORMED AT : SRL Ltd

Mumbai, 400062



PATIENT NAME: RAJSHEKAR PABBA	REF. DOCTOR : SELF		
	ACCESSION NO : 0002WB021401	AGE/SEX : 45 Years Male	
	PATIENT ID : RAJSM3110772	DRAWN :11/02/2023 08:47:29	
	CLIENT PATIENT ID:	RECEIVED : 11/02/2023 08:48:40	
	ABHA NO :	REPORTED :13/02/2023 11:36:56	
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units	

OMEGA 3 FATS SUPPLEMENTS

RELEVANT NON PATHOLOGY DIAGNOSTICS REMARKS / RECOMMENDATIONS USG-GRADE I FATTY LIVER RAISED ESR,RAISED HBA1C,RAISED FBS,RAISED PPBS,LOW HDL CHOLESTEROL,RAISED LDL MONITOR BLOOD SUGAR REDUCE PURINE RICH FOODS

FOLLOW UP WITH PHYSICIAN FOR HYPERGLYCEMIA

Sexamarkas

Dr. Swati Karmarkar, MD,DNB,DMRD Consultant Radiologist

terkl

Dr. J N Shukla ,MBBS, AFIH Consultant Physician





View Report

Page 4 Of 23

View Details



PERFORMED AT : SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



PATIENT NAME : RAJSHEKAR PABBA	REF. DOCTOR : SELF		
	ACCESSION NO : 0002WB021401	AGE/SEX :45 Years Male	
	PATIENT ID : RAJSM3110772	DRAWN :11/02/2023 08:47:29	
	CLIENT PATIENT ID:	RECEIVED : 11/02/2023 08:48:40	
	ABHA NO :	REPORTED :13/02/2023 11:36:56	
Test Report Status <u>Final</u>	Results	Units	

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE **ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN**

- GRADE I FATTY LIVER.

Interpretation(s)

MEDICAL

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

Straimarkal

Dr. Swati Karmarkar, MD, DNB, DMRD **Consultant Radiologist**

Harkl

Dr. J N Shukla ,MBBS, AFIH **Consultant Physician**



View Report

Page 5 Of 23

Details



PERFORMED AT : SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956





PATIENT NAME : RAJSHEKAR PABBA	REF. DOCTOR : SELF		
	ACCESSION NO : 0002WB021401	AGE/SEX : 45 Years Male	
	PATIENT ID : RAJSM3110772	DRAWN :11/02/2023 08:47:29	
	CLIENT PATIENT ID:	RECEIVED : 11/02/2023 08:48:40	
	ABHA NO :	REPORTED :13/02/2023 11:36:56	
Test Report Status <u>Final</u>	Results Biological	Reference Interval Units	

Н	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECK UP AB	OVE 40 MALE		
BLOOD COUNTS, EDTA WHOLE BLOOD			
HEMOGLOBIN (HB) METHOD : PHOTOMETRIC MEASUREMENT	15.1	13.0 - 17.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD : COULTER PRINCIPLE	5.22	4.5 - 5.5	mil/µL
WHITE BLOOD CELL (WBC) COUNT METHOD : COULTER PRINCIPLE	8.00	4.0 - 10.0	thou/µL
PLATELET COUNT METHOD : ELECTRONIC IMPEDENCE & MICROSCOPY	225	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD : CALCULATED PARAMETER	45.6	40.0 - 50.0	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	87.5	83.0 - 101.0	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED PARAMETER	28.9	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER	33.0	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM	14.0	11.6 - 14.0	%
MENTZER INDEX	16.8		
MEAN PLATELET VOLUME (MPV) METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM	9.1	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS METHOD : VCSN TECHNOLOGY/ MICROSCOPY	53	40 - 80	%
LYMPHOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY	36	20 - 40	%
MONOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY	7	2.0 - 10.0	%
EOSINOPHILS METHOD : VCSN TECHNOLOGY/ MICROSCOPY	3	1.0 - 6.0	%



Dr. Reena Mittal, MD Senior Consultant Hematopathologist



Dr. Sushant Chikane Consultant Pathologist



View Report

View Details







PATIENT NAME : RAJSHEKAR PABBA	REF. DOCTOF	REF. DOCTOR : SELF		
	ACCESSION NO : 0002WB021401	AGE/SEX : 45 Years Male		
	PATIENT ID : RAJSM3110772	DRAWN :11/02/2023 08:47:29		
	CLIENT PATIENT ID:	RECEIVED : 11/02/2023 08:48:40		
	ABHA NO :	REPORTED :13/02/2023 11:36:56		
Test Report Status Final	Results Biologi	cal Reference Interval Units		

Results	Biological Reference	
1	0 - 1	%
4.24	2.0 - 7.0	thou/µL
2.88	1.0 - 3.0	thou/µL
0.56	0.2 - 1.0	thou/µL
0.24	0.02 - 0.50	thou/µL
0.08	0.02 - 0.10	thou/µL
1.5		
	1 4.24 2.88 0.56 0.24 0.08	4.24 2.0 - 7.0 2.88 1.0 - 3.0 0.56 0.2 - 1.0 0.24 0.02 - 0.50 0.08 0.02 - 0.10

Interpretation(s) BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait. WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR <

3.3, COVID-19 patients tend to show mild disease.

Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Reena Mittal, MD Senior Consultant Hematopathologist

Dr. Sushant Chikane Consultant Pathologist





View Report

Page 7 Of 23

View Details



PERFORMED AT : SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA Tel : 9111591115, Fax :

CIN - U74899PB1995PLC045956





REF. DOCTOR : SELF PATIENT NAME : RAJSHEKAR PABBA ACCESSION NO : 0002WB021401 AGE/SEX :45 Years Male :11/02/2023 08:47:29 PATIENT ID : RAJSM3110772 DRAWN CLIENT PATIENT ID: RECEIVED : 11/02/2023 08:48:40 REPORTED :13/02/2023 11:36:56 ABHA NO : **Test Report Status Biological Reference Interval** <u>Final</u> Results Units

HAEMATOLOGY MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE **ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE** BLOOD E.S.R 18 High 0 - 14 mm at 1 hr METHOD : AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)

Interpretation(s) ERYTHROCYTE SEDIMENTATION RATE (ESR),WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. **TEST INTERPRETATION**

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

Dr. Reena Mittal, MD Senior Consultant Hematopathologist

Dr. Sushant Chikane Consultant Pathologist



View Repor

Page 8 Of 23



PERFORMED AT : SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA Tel : 9111591115, Fax CIN - U74899PB1995PLC045956





PATIENT NAME : RAJSHEKAR PABBA REF. DOCTOR : SELF ACCESSION NO : 0002WB021401 AGE/SEX :45 Years Male PATIENT ID DRAWN :11/02/2023 08:47:29 : RAJSM3110772 CLIENT PATIENT ID: RECEIVED : 11/02/2023 08:48:40 REPORTED :13/02/2023 11:36:56 ABHA NO : **Test Report Status** Results **Biological Reference Interval** Units <u>Final</u>

IMMUNOHAEMATOLOGY MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD ABO GROUP В METHOD : HAEMAGGLUTINATION (AUTOMATED) RH TYPE POSITIVE

METHOD : HAEMAGGLUTINATION (AUTOMATED)

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Sushant Chikane **Consultant Pathologist**





PERFORMED AT : SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA Tel : 9111591115, Fax CIN - U74899PB1995PLC045956

View Repor



Page 9 Of 23





PATIENT NAME : RAJSHEKAR PABBA REF. DOCTOR : SELF ACCESSION NO : 0002WB021401 AGE/SEX :45 Years Male PATIENT ID DRAWN :11/02/2023 08:47:29 : RAJSM3110772 CLIENT PATIENT ID: RECEIVED : 11/02/2023 08:48:40 REPORTED :13/02/2023 11:36:56 ABHA NO : Biological Reference Interval **Test Report Status** Results Units **Final** BIOCHEMISTRY MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD 6.7 High HBA1C Non-diabetic Adult < 5.7 % Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = 6.5Therapeutic goals: < 7.0Action suggested : > 8.0 (ADA Guideline 2021) METHOD : ION- EXCHANGE HPLC ESTIMATED AVERAGE GLUCOSE(EAG) 145.6 High mg/dL < 116 **GLUCOSE FASTING, FLUORIDE PLASMA** FBS (FASTING BLOOD SUGAR) 117 High Normal <100 mg/dL Impaired fasting glucose:100 to 125 Diabetes mellitus: > = 126 (on more than 1 occassion) (ADA guidelines 2021) METHOD : SPECTROPHOTOMETRY HEXOKINASE **GLUCOSE, POST-PRANDIAL, PLASMA** PPBS(POST PRANDIAL BLOOD SUGAR) 154 High Normal <140 mg/dL Impaired glucose tolerance:140 to 199


METHOD : SPECTROPHOTOMETRY HEXOKINASE LIPID PROFILE, SERUM CHOLESTEROL, TOTAL

Desirable : < 200 162 mg/dL Borderline : 200 - 239 High : > / = 240METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - CHOLETSEROL OXIDASE, ESTERASE, PEROXIDASE TRIGLYCERIDES 111 Normal: < 150 mg/dL Borderline high: 150 - 199 High: 200 - 499

METHOD : SPECTROPHOTOMETRY, ENZYMATIC ENDPOINT WITH GLYCEROL BLANK

8. wada

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 10 Of 23



Diabetes mellitus : > = 200 (on more than 1 occassion)

ADA guideline 2021

Very High: >/= 500



Test Report Status

Final



Biological Reference Interval



Units

PATIENT NAME : RAJSHEKAR PABBA REF. DOCTOR : SELF ACCESSION NO : 0002WB021401 AGE/SEX :45 Years Male PATIENT ID DRAWN :11/02/2023 08:47:29 : RAJSM3110772 CLIENT PATIENT ID: RECEIVED : 11/02/2023 08:48:40 REPORTED :13/02/2023 11:36:56 ABHA NO :

Results

Test Report Status Final	Results	Biological Reference Interval Units	
HDL CHOLESTEROL	30 Low	At Risk: < 40 mg/dL	
		Desirable: > or = 60	
METHOD : SPECTROPHOTOMETRY, HOMOGENEOUS DIRECT	ENZYMATIC COLORIMETRIC		
CHOLESTEROL LDL	110 High	Optimal : < 100 mg/dL Near optimal/above optimal : 100-129	
		Borderline high : $130-159$ High : $160-189$ Very high : = 190	
METHOD : CALCULATED PARAMETER			
NON HDL CHOLESTEROL	132 High	Desirable : < 130 mg/dL Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : > $/ = 220$	
METHOD : CALCULATED PARAMETER			
VERY LOW DENSITY LIPOPROTEIN METHOD : CALCULATED PARAMETER	22.0	< or = 30.0 mg/dL	
CHOL/HDL RATIO	5.4 High	Low Risk : 3.3 - 4.4 Average Risk : 4.5 - 7.0 Moderate Risk : 7.1 - 11.0 High Risk : > 11.0	
METHOD : CALCULATED PARAMETER		5	
LDL/HDL RATIO	4.0 High	Desirable/Low Risk : 0.5 - 3.0 Borderline/Moderate Risk : 3.1 - 6.0 High Risk : > 6.0	
METHOD : CALCULATED PARAMETER			

METHOD : CALCULATED PARAMETER

Interpretation(s)

1) Cholesterol levels help assess the patient risk status and to follow the progress of patient under treatment to lower serum cholesterol concentrations.


2) Serum Triglyceride (TG) are a type of fat and a major source of energy for the body. Both quantity and composition of the diet impact on plasma triglyceride concentrations. Elevations in TG levels are the result of overproduction and impaired clearance. High TG are associated with increased risk for CAD (Coronary artery disease) in patients with other risk factors, such as low HDL-C, some patient groups with elevated apolipoprotein B concentrations, and patients with forms of LDL that may be particularly atherogenic.

3)HDL-C plays a crucial role in the initial step of reverse cholesterol transport, this considered to be the primary atheroprotective function of HDL

.S.wadal

SRL Ltd

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 11 Of 23



Vie<u>w Report</u>







REF. DOCTOR : SELF PATIENT NAME : RAJSHEKAR PABBA ACCESSION NO : 0002WB021401 AGE/SEX :45 Years Male PATIENT ID :11/02/2023 08:47:29 : RAJSM3110772 DRAWN CLIENT PATIENT ID: RECEIVED : 11/02/2023 08:48:40 REPORTED :13/02/2023 11:36:56 ABHA NO : Biological Reference Interval **Test Report Status** Results Units <u>Final</u>

4) LDL -C plays a key role in causing and influencing the progression of atherosclerosis and, in particular, coronary sclerosis. The majority of cholesterol stored in atherosclerotic plaques originates from LDL, thus LDL-C value is the most powerful clinical predictor.

5)Non HDL cholesterol: Non-HDL-C measures the cholesterol content of all atherogenic lipoproteins, including LDL hence it is a better marker of risk in both primary and secondary prevention studies. Non-HDL-C also covers, to some extent, the excess ASCVD risk imparted by the sdLDL, which is significantly more atherogenic than the normal large buoyant particles, an elevated non-HDL-C indirectly suggests greater proportion of the small, dense variety of LDL particles

Serum lipid profile is measured for cardiovascular risk prediction.Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category			
Extreme risk group	A.CAD with > 1 feature of high risk group		
	B. CAD with > 1 feature of Very high risk	group or recurrent ACS (within 1 year) despite LDL-C	
	< or $=$ 50 mg/dl or polyvascular disease		
Very High Risk	1. Established ASCVD 2. Diabetes with 2	major risk factors or evidence of end organ damage 3.	
	Familial Homozygous Hypercholesterolemi	a	
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end		
	organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6.		
	Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid		
	plaque		
Moderate Risk	2 major ASCVD risk factors		
Low Risk	0-1 major ASCVD risk factors		
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors			
1. Age $>$ or $=$ 45 year	1. Age $>$ or $=$ 45 years in males and $>$ or $=$ 55 years in females 3. Current Cigarette smoking or tobacco use		
2. Family history of premature ASCVD 4. High blood pressure		4. High blood pressure	
5. Low HDL			


Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
Category A	< OR = 30)	<or 60)<="" =="" td=""><td></td><td></td></or>		
Extreme Risk Group	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>> 30</td><td>>60</td></or></td></or>	<or 60<="" =="" td=""><td>> 30</td><td>>60</td></or>	> 30	>60
Category B				
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160

*After an adequate non-pharmacological intervention for at least 3 months.

8. wada

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 12 Of 23









PATIENT NAME : RAJSHEKAR PABBA	REF. DOCTOR	SELF
	ACCESSION NO : 0002WB021401 PATIENT ID : RAJSM3110772 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :45 Years Male DRAWN :11/02/2023 08:47:29 RECEIVED :11/02/2023 08:48:40 REPORTED :13/02/2023 11:36:56
Test Report Status Final	Results Biologi	cal Reference Interval Units


References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -DIAZO METHOD	0.55	Upto 1.2	mg/dL
BILIRUBIN, DIRECT METHOD : SPECTROPHOTOMETRY, JENDRASSIK & GROFF - DIAZOTIZ	0.25 ATION	< or = 0.3	mg/dL
BILIRUBIN, INDIRECT METHOD : CALCULATED PARAMETER	0.30	0.0 - 0.9	mg/dL
TOTAL PROTEIN METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -BIURET, REAGENT	7.2 F BLANK, SERUM BLANK	6.0 - 8.0	g/dL
	4.3	3.97 - 4.94	g/dL
METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - DY GLOBULIN METHOD : CALCULATED PARAMETER	2.9	2.0 - 3.5	g/dL
ALBUMIN/GLOBULIN RATIO	1.5	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	21	Upto 40	U/L
METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD : SPECTROPHOTOMETRY, WITHOUT PYRIDOXAL PHOSPHATE	25	Upto 41	U/L
ALKALINE PHOSPHATASE METHOD : SPECTROPHOTOMETRY, PNPP, AMP BUFFER - IFCC	78	40 - 129	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC - G-GL	20 _UTAMYL-CARBOXY-NITROANILIDE - I	< 60 FCC	U/L
LACTATE DEHYDROGENASE METHOD : SPECTROPHOTOMETRY, LACTATE TO PYRUVATE - UV-IFCC	137	< 232	U/L
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN METHOD : SPECTROPHOTOMETRY, UREASE -COLORIMETRIC	7	6 - 20	mg/dL
CREATININE, SERUM			
CREATININE METHOD : SPECTROPHOTOMETRY, JAFFE'S ALKALINE PICRATE KINET	1.15 C - RATE BLANKED - IFCC-IDMS STAI	0.90 - 1.30 NDARIZED	mg/dL

BUN/CREAT RATIO

.S.Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 13 Of 23



View Details








PATIENT NAME : RAJSHEKAR PABBA	RE	F. DOCTOR : SELF	
	ACCESSION NO : 0002WE	3021401 AGE/SEX :45	5 Years Male
	PATIENT ID : RAJSM31	.10772 DRAWN :1	1/02/2023 08:47:29
	CLIENT PATIENT ID:	RECEIVED :1	1/02/2023 08:48:40
	ABHA NO :	REPORTED :13	3/02/2023 11:36:56
Test Report Status <u>Final</u>	Results	Biological Reference Ir	iterval Units
BUN/CREAT RATIO METHOD : CALCULATED PARAMETER	6.10 Low	8 - 15	
URIC ACID, SERUM			
URIC ACID	8.5 High	3.4 - 7.0	mg/dL
METHOD : SPECTROPHOTOMETRY, ENZYMATIC COLORIMETRIC- U	RICASE		
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	7.2	6.0 - 8.0	g/dL
METHOD : SPECTROPHOTOMETRY, COLORIMETRIC -BIURET, REAG	ENT BLANK, SERUM BLANK		
ALBUMIN, SERUM			<i></i>
	4.3	3.97 - 4.94	g/dL
METHOD : SPECTROPHOTOMETRY, BROMOCRESOL GREEN(BCG) - GLOBULIN	DIE BINDING		
GLOBULIN	2.9	2.0 - 3.5	g/dL
METHOD : CALCULATED PARAMETER	2.5	2.0 - 5.5	9/02
ELECTROLYTES (NA/K/CL), SERUM			
SODIUM, SERUM	137	136 - 145	mmol/L
METHOD : ISE INDIRECT			
POTASSIUM, SERUM	4.40	3.5 - 5.1	mmol/L
METHOD : ISE INDIRECT			
CHLORIDE, SERUM	104	98 - 106	mmol/L
METHOD : ISE INDIRECT			

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative.corticosteroids, diuretics.

S. S. Wadal

Dr. Sneha Wadalkar,M.D (Reg.no.MMC2012/06/1868) Junior Biochemist







Vie<u>w</u> Details







REF. DOCTOR : SELF PATIENT NAME : RAJSHEKAR PABBA ACCESSION NO : 0002WB021401 AGE/SEX :45 Years Male :11/02/2023 08:47:29 PATIENT ID : RAJSM3110772 DRAWN CLIENT PATIENT ID: RECEIVED : 11/02/2023 08:48:40 REPORTED :13/02/2023 11:36:56 ABHA NO :

Test Report Status Results **Biological Reference Interval Final** Units

Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison' s disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high-	Increased in: Renal failure, nephrotic syndrome, RTA,dehydration, overtreatment with saline,hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis,hyperadrenocorticism. Drugs: acetazolamide,androgens,
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	dose trimethoprim-sulfamethoxazole. Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	hydrochlorothiazide,salicylates. Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s) GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2.Diagnosing diabetes.

3.Identifying patients at increased risk for diabetes (prediabetes). The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
 2. eAG gives an evaluation of blood glucose levels for the last couple of months.
 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

II.Vitamin C & E are reported to falsely lower test results (possibly by inhibiting glycation of hemoglobin. III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia,uremia, hyperbilirubinemia, chronic alcoholism,chronic ingestion of salicylates & opiates

addiction are reported to interfere with some assay methods, falsely increasing results.

IV.Interference of hemoglobinopathies in HbA1c estimation is seen in a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.) c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy GLUCOSE FASTING, FLUORIDE PLASMA-**TEST DESCRIPTION**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides.

Decreased in

Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical,

stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin, ethanol, propranolol; sulfonylureas,tolbutamide, and other oral hypoglycemic agents.

NOTE:

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 15 Of 23

Details



PERFORMED AT : SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA Tel : 9111591115, Fax CIN - U74899PB1995PLC045956





REF. DOCTOR : SELF PATIENT NAME : RAJSHEKAR PABBA ACCESSION NO : 0002WB021401 AGE/SEX :45 Years Male :11/02/2023 08:47:29 PATIENT ID : RAJSM3110772 DRAWN CLIENT PATIENT ID: RECEIVED : 11/02/2023 08:48:40 REPORTED :13/02/2023 11:36:56 ABHA NO **Test Report Status** Results Biological Reference Interval **Final** Units

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin is also elevated more than unconjugated (indirect) bilirubin is also elevated more than unconjugated (indirect) bilirubin there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget'''s disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson'''s disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and seen in hypothologinates and h system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom"'s disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.Human serum albumin is the most abundant protein in human blood plasma.It is produced in the liver.Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to: • Blockage in the urinary tract

- · Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
- Loss of body fluid (dehydration)
- Muscle problems, such as breakdown of muscle fibers

• Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

Myasthenia Gravis

Muscular dystrophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome

Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum.. Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum

protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

S.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 16 Of 23

View Report

/iew Details



PERFORMED AT : SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA Tel : 9111591115, Fax CIN - U74899PB1995PLC045956





PATIENT NAME : RAJSHEKAR PABBA REF. DOCTOR : SELF ACCESSION NO : 0002WB021401 AGE/SEX :45 Years Male PATIENT ID : RAJSM3110772 DRAWN :11/02/2023 08:47:29 CLIENT PATIENT ID: RECEIVED : 11/02/2023 08:48:40 REPORTED :13/02/2023 11:36:56 ABHA NO : Test Report Status Final Results Biological Reference Interval Units

Test Report Status	<u>Final</u>	Results	Biological Reference I	Interval Units
	CLINI	CAL PATH - URINALYS	IS	
MEDI WHEEL FULL BO	DY HEALTH CHECK UP A	BOVE 40 MALE		
PHYSICAL EXAMINAT	ION, URINE			
COLOR		PALE YELLOW		
APPEARANCE		CLEAR		
CHEMICAL EXAMINAT	ION, URINE			
PH		6.0	5.00 - 7.50	
SPECIFIC GRAVITY		1.025	1.010 - 1.030	
PROTEIN		NOT DETECTED	NOT DETECTED	
GLUCOSE		NOT DETECTED	NOT DETECTED	
KETONES		NOT DETECTED	NOT DETECTED	
BLOOD		NOT DETECTED	NOT DETECTED	
BILIRUBIN		NOT DETECTED	NOT DETECTED	
UROBILINOGEN		NOT DETECTED		
NITRITE		NOT DETECTED	NOT DETECTED	
LEUKOCYTE ESTERAS	E	NOT DETECTED	NOT DETECTED	
MICROSCOPIC EXAMI	NATION, URINE			
RED BLOOD CELLS		NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)		0-1	0-5	/HPF
EPITHELIAL CELLS		0-1	0-5	/HPF
CASTS		NOT DETECTED		
CRYSTALS		NOT DETECTED		

NOT DETECTED

NOT DETECTED

NOT DETECTED

NOT DETECTED

METHOD : URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEGRATED AUTOMATED SYSTEM

Interpretation(s)

BACTERIA

YEAST

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment

S.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist











PATIENT NAME : RAJSHEKAR PABBA REF. DOCTOR : SELF ACCESSION NO : 0002WB021401 AGE/SEX :45 Years Male PATIENT ID : RAJSM3110772 DRAWN :11/02/2023 08:47:29 CLIENT PATIENT ID: RECEIVED : 11/02/2023 08:48:40 REPORTED :13/02/2023 11:36:56 ABHA NO :

Test Report Status	Final	Results
rest Report Status	i mai	ixesuits

Biological Reference Interval Units

Glucose	Diabetes or kidney disease	
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst	
	Liver disease such as hepatitis or cirrhosis	
Urobilinogen	* · · · · · · · · · · · · · · · · · · ·	
Blood	Renal or genital disorders/trauma	
Bilirubin	Liver disease	
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases	
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions	
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time	
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein	
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases	
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice	
Uric acid	arthritis	
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.	
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis	

S.S. Wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 18 Of 23



PERFORMED AT : SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062 MAHARÁSHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956





PATIENT NAME : RAJSHEKAR PABBA REF. DOCTOR : SELF ACCESSION NO : 0002WB021401 AGE/SEX :45 Years Male :11/02/2023 08:47:29 PATIENT ID : RAJSM3110772 DRAWN CLIENT PATIENT ID: RECEIVED : 11/02/2023 08:48:40 REPORTED :13/02/2023 11:36:56 ABHA NO :

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units
--------------------	--------------	---------	--------------------------------------	-------

C	LINICAL PATH - STOOL ANAL	/SIS	
MEDI WHEEL FULL BODY HEALTH CHEC	K UP ABOVE 40 MALE		
PHYSICAL EXAMINATION, STOOL			
COLOUR	BROWN		
CONSISTENCY	SEMI FORMED		
MUCUS	NOT DETECTED	NOT DETECTED	
VISIBLE BLOOD	ABSENT	ABSENT	
ADULT PARASITE	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION			
CHEMICAL EXAMINATION, STOOL			
STOOL PH	6.0		
OCCULT BLOOD	DETECTED	NOT DETECTED	
METHOD : MODIFIED GUAIAC METHOD			
MICROSCOPIC EXAMINATION, STOOL			
PUS CELLS	NOT DETECTED		/hpf
RED BLOOD CELLS	2-3	NOT DETECTED	/HPF
METHOD : MICROSCOPIC EXAMINATION			
CYSTS	NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION			
OVA METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED		
	NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION	NOT DETECTED	NOT DETECTED	
TROPHOZOITES	NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION			
FAT	ABSENT		
CHARCOT LEYDEN CRYSTALS	ABSENT		
Interpretation(c)			

Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION
Pus cells	Pus in the stool is an indication of infection

Dr. Ekta Patil, MD (Reg.No. MMC2008/04/1142) Senior Microbiologist

Page 19 Of 23



Details







PATIENT NAME : RAJSHEKAR PABBA REF. DOCTOR : SELF ACCESSION NO : 0002WB021401 AGE/SEX :45 Years Male PATIENT ID DRAWN :11/02/2023 08:47:29 : RAJSM3110772 CLIENT PATIENT ID: RECEIVED : 11/02/2023 08:48:40 REPORTED :13/02/2023 11:36:56 ABHA NO :

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units	
--------------------	--------------	---------	--------------------------------------	-------	--

Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis		
Parasites	Infection of the digestive system. Stool examination for ova and parasite detect presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days. Stool specimens for parasitic examination should be collecte before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.		
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to bacteria or viruses.		
Charcot-Leyden crystal	Parasitic diseases.		
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.		
Frank blood	Bleeding in the rectum or colon.		
Occult blood	Occult blood indicates upper GI bleeding.		
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.		
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.		
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.		
рН	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.		

ADDITIONAL STOOL TESTS:

- Stool Culture:- This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if 1. treatment for GI infection worked.
- Fecal Calprotectin: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) 2. from Irritable Bowel Syndrome (IBS).
- Fecal Occult Blood Test(FOBT): This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia. 3.
- Clostridium Difficile Toxin Assay: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to 4. overuse of broad spectrum antibiotics which alter the normal GI flora.
- Biofire (Film Array) GI PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array 5. Test (Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus, parasite and other opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.
- Rota Virus Immunoassay: This test is recommended in severe gastroenteritis in infants & children associated with watery 6. diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.

Dr. Ekta Patil, MD (Reg.No. MMC2008/04/1142) Senior Microbiologist



Page 20 Of 23

Details








PATIENT NAME : RAJSHEKAR PABBA	REF. DOCTOR : SELF				
	ACCESSION NO : 0002WB0214	401 AGE/SEX :45 Years Male			
	PATIENT ID : RAJSM311077	72 DRAWN :11/02/2023 08:47:29			
	CLIENT PATIENT ID:	RECEIVED : 11/02/2023 08:48:40			
	ABHA NO :	REPORTED :13/02/2023 11:36:56			
	1				
Test Report Status <u>Final</u>	Results Bi	iological Reference Interval Units			



Dr. Ekta Patil,MD (Reg.No. MMC2008/04/1142) Senior Microbiologist



Page 21 Of 23





View Details







REF. DOCTOR : SELF PATIENT NAME : RAJSHEKAR PABBA ACCESSION NO : 0002WB021401 AGE/SEX :45 Years Male PATIENT ID DRAWN :11/02/2023 08:47:29 : RAJSM3110772 CLIENT PATIENT ID: RECEIVED : 11/02/2023 08:48:40 REPORTED :13/02/2023 11:36:56 ABHA NO : Results

Test Report Status Final

Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECK U	L FULL BODY HEALTH CHECK UP ABOVE 40 MALE ANFL SERUM		
THYROID PANEL, SERUM			
ТЗ	140.0	80.0 - 200.0	ng/dL
METHOD : COMPETITIVE ELECTROCHEMILUMINESCENCE IMM	IUNOASSAY		
T4	7.64	5.10 - 14.10	µg/dL
METHOD : COMPETITIVE ELECTROCHEMILUMINESCENCE IMM	IUNOASSAY		
TSH (ULTRASENSITIVE)	1.890	0.270 - 4.200	µIU/mL
METHOD : SANDWICH ELECTROCHEMILUMINESCENCE IMMU	NOASSAY		

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
					Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
					(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism

.S.wadal

Dr. Sneha Wadalkar, M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 22 Of 23







 PATIENT NAME : RAJSHEKAR PABBA
 REF. DOCTOR : SELF

 ACCESSION NO : 0002WB021401
 AGE/SEX : 45 Years
 Male

 PATIENT ID : RAJSM3110772
 DRAWN : 11/02/2023 08:47:29

 CLIENT PATIENT ID:
 ABHA NO :
 RECEIVED : 11/02/2023 08:48:40

Test Report Status Final Results Biological Reference Interval Unit	ts
---	----

8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies
REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association duriing pregnancy and Postpartum, 2011.					

NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

End Of Report Please visit www.srlworld.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.

2. All tests are performed and reported as per the

turnaround time stated in the SRL Directory of Services.

3. Result delays could occur due to unforeseen

circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.

- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type

iv. Discrepancy between identification on specimen container label and test requisition form

5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.

6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.

7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.

8. Test results cannot be used for Medico legal purposes.

- 9. In case of queries please call customer care
- (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



Dr. Sneha Wadalkar,M.D (Reg.no.MMC2012/06/1868) Junior Biochemist



Page 23 Of 23

View Repor

View Details



PERFORMED AT : SRL Ltd PRIME SQUARE BUILDING,PLOT NO 1,GAIWADI INDUSTRIAL ESTATE,S.V. ROAD,GOREGAON (W) Mumbai, 400062 MAHARASHTRA, INDIA Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956